Literature DB >> 19110059

Minocycline restores striatal tyrosine hydroxylase in GDNF heterozygous mice but not in methamphetamine-treated mice.

Heather A Boger1, Lawrence D Middaugh, Ann-Charlotte Granholm, Jacqueline F McGinty.   

Abstract

Inflammation, phospho-p38 MAPK activation, and a reduction in glial cell line-derived neurotrophic factor (GDNF) occur in Parkinson's disease. Microglial activation in the substantia nigra and a tyrosine hydroxylase deficit in the striatum of 3-month-old GDNF heterozygous (GDNF(+/-)) mice were previously reported and both were exacerbated by a toxic methamphetamine binge. The current study assessed the effects of minocycline on these methamphetamine-induced effects. Minocycline (45 mg/kg, i.p.x 14 days post-methamphetamine or saline injections) reduced microglial activation and phospho-p38 MAPK in the substantia nigra of saline-treated GDNF(+/-) mice and in methamphetamine-treated wildtype and GDNF(+/-) mice. Although minocycline increased tyrosine hydroxylase-immunoreactivity in GDNF(+/-) mice, it did not attenuate the methamphetamine-induced reduction of tyrosine hydroxylase. The results suggest that neuroinflammation is deleterious to the dopamine system of GDNF(+/-) mice but is not the primary cause of methamphetamine-induced damage to the dopamine system in either GDNF(+/-) or wildtype mice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19110059      PMCID: PMC2645227          DOI: 10.1016/j.nbd.2008.11.013

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  51 in total

1.  Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia.

Authors:  T Tikka; B L Fiebich; G Goldsteins; R Keinanen; J Koistinaho
Journal:  J Neurosci       Date:  2001-04-15       Impact factor: 6.167

2.  Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease.

Authors:  D C Wu; Vernice Jackson-Lewis; Miquel Vila; Kim Tieu; Peter Teismann; Caryn Vadseth; Dong-Kug Choi; Harry Ischiropoulos; Serge Przedborski
Journal:  J Neurosci       Date:  2002-03-01       Impact factor: 6.167

3.  Inhibitors of p38 MAP kinase increase the survival of transplanted dopamine neurons.

Authors:  W M Zawada; M K Meintzer; P Rao; J Marotti; X Wang; J E Esplen; E D Clarkson; C R Freed; K A Heidenreich
Journal:  Brain Res       Date:  2001-02-09       Impact factor: 3.252

4.  Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.

Authors:  Y Du; Z Ma; S Lin; R C Dodel; F Gao; K R Bales; L C Triarhou; E Chernet; K W Perry; D L Nelson; S Luecke; L A Phebus; F P Bymaster; S M Paul
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-27       Impact factor: 11.205

5.  Expression of microglial response factor-1 in microglia and macrophages following cerebral ischemia in the rat.

Authors:  H Kato; S Tanaka; T Oikawa; T Koike; A Takahashi; Y Itoyama
Journal:  Brain Res       Date:  2000-11-03       Impact factor: 3.252

6.  Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia.

Authors:  T M Tikka; J E Koistinaho
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

7.  A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window.

Authors:  J Yrjänheikki; T Tikka; R Keinänen; G Goldsteins; P H Chan; J Koistinaho
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

8.  N-Methyl-D-aspartate receptors and p38 mitogen-activated protein kinase are required for cAMP-dependent cyclase response element binding protein and Elk-1 phosphorylation in the striatum.

Authors:  E S Choe; J F McGinty
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

9.  Dentate granule neuron apoptosis and glia activation in murine hippocampus induced by trimethyltin exposure.

Authors:  A Fiedorowicz; I Figiel; B Kamińska; M Zaremba; S Wilk; B Oderfeld-Nowak
Journal:  Brain Res       Date:  2001-09-07       Impact factor: 3.252

Review 10.  Protection against Parkinson's disease progression: clinical experience.

Authors:  Peter A LeWitt; Danette C Taylor
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

View more
  14 in total

1.  Glial cell-line derived neurotrophic factor (GDNF) replacement attenuates motor impairments and nigrostriatal dopamine deficits in 12-month-old mice with a partial deletion of GDNF.

Authors:  Ofelia M Littrell; Ann-Charlotte Granholm; Greg A Gerhardt; Heather A Boger
Journal:  Pharmacol Biochem Behav       Date:  2013-01-02       Impact factor: 3.533

2.  Chronic wheel running-induced reduction of extinction and reinstatement of methamphetamine seeking in methamphetamine dependent rats is associated with reduced number of periaqueductal gray dopamine neurons.

Authors:  Jeffery C Sobieraj; Airee Kim; McKenzie J Fannon; Chitra D Mandyam
Journal:  Brain Struct Funct       Date:  2014-10-02       Impact factor: 3.270

Review 3.  Role of microglia in methamphetamine-induced neurotoxicity.

Authors:  Enquan Xu; Jianuo Liu; Han Liu; Xiaobei Wang; Huangui Xiong
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2017-06-15

4.  Prenatal LPS increases inflammation in the substantia nigra of Gdnf heterozygous mice.

Authors:  Ann-Charlotte Granholm; Vandana Zaman; Jennifer Godbee; Michael Smith; Riad Ramadan; Claudia Umphlet; Patrick Randall; Narayan R Bhat; Baerbel Rohrer; Lawrence D Middaugh; Heather A Boger
Journal:  Brain Pathol       Date:  2010-12-08       Impact factor: 6.508

Review 5.  Nucleus accumbens invulnerability to methamphetamine neurotoxicity.

Authors:  Donald M Kuhn; Mariana Angoa-Pérez; David M Thomas
Journal:  ILAR J       Date:  2011

6.  Methamphetamine induces low levels of neurogenesis in striatal neuron subpopulations and differential motor performance.

Authors:  I K Tulloch; L Afanador; L Baker; D Ordonez; H Payne; I Mexhitaj; E Olivares; A Chowdhury; J A Angulo
Journal:  Neurotox Res       Date:  2014-02-19       Impact factor: 3.911

Review 7.  A dual-hit animal model for age-related parkinsonism.

Authors:  Heather A Boger; Ann-Charlotte Granholm; Jacqueline F McGinty; Lawrence D Middaugh
Journal:  Prog Neurobiol       Date:  2009-10-21       Impact factor: 11.685

8.  Cyclooxygenase activity contributes to the monoaminergic damage caused by serial exposure to stress and methamphetamine.

Authors:  Nicole A Northrop; Bryan K Yamamoto
Journal:  Neuropharmacology       Date:  2013-05-02       Impact factor: 5.250

9.  Methamphetamine treatment causes delayed decrease in novelty-induced locomotor activity in mice.

Authors:  Irina N Krasnova; Amber B Hodges; Bruce Ladenheim; Raina Rhoades; Crystal G Phillip; Angela Cesena; Ekaterina Ivanova; Christine F Hohmann; Jean Lud Cadet
Journal:  Neurosci Res       Date:  2009-06-24       Impact factor: 3.304

Review 10.  Methamphetamine-induced dopaminergic neurotoxicity as a model of Parkinson's disease.

Authors:  Eun-Joo Shin; Ji Hoon Jeong; Yeonggwang Hwang; Naveen Sharma; Duy-Khanh Dang; Bao-Trong Nguyen; Seung-Yeol Nah; Choon-Gon Jang; Guoying Bing; Toshitaka Nabeshima; Hyoung-Chun Kim
Journal:  Arch Pharm Res       Date:  2021-07-20       Impact factor: 4.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.